MedTrace Logo

Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy

NCT01907191 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-08-16

Study results available
· View outcomes & findings →

Summary

This study is being undertaken to compare the pain control using either bupivacaine versus liposomal bupivacaine. Liposomal bupivacaine can potentially provide pain relief lasting up to 72 hours while regular bupivacaine can provide pain relief up to 12 hours

Conditions

  • Hip Injuries

Interventions

DRUG

liposomal bupivacaine

(Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy

DRUG

Bupivacaine

(around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy

Sponsors & Collaborators

  • Trinity Health Of New England

    lead OTHER

Principal Investigators

  • Sanjay Sinha, MD · Saint Francis Hospital and Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2019-01-30
Completion
2019-01-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907191 on ClinicalTrials.gov